Immunogenicity evaluation of RBD subunit vaccine formulated with CpG 1826 adjuvant
Objective To evaluate immunogenicity of receptor binding domain(RBD)subunit vaccine formulated with CpG 1826 adjuvant in mice.Methods BALB/c mice were intramuscularly inoculated with two doses of RBD recombinant protein formulated with CpG 1826 adjuvant.The level of the specific IgG antibodies and neutralizing antibodies(NAbs)in serum were detected by ELISA and microneutralization assay,respectively.The effector T lymphocytes secreting IFN-γ and IL-4 in mice spleen were quantified by ELISpot.Results RBD protein formulated with CpG 1826 adjuvant induced a high level of specific IgG antibodies(18 820.27)and NAbs,which had cross-neutralizing activity against SARS-CoV-2 prototype(776),BA.2(676),and XBB.1.5(97)variants.The specific effector T lymphocytes secreting IFN-γ and IL-4 in mice spleen were 382.4±16.1 and 180.6±4.78,respectively.Combined with an IgG1/IgG2a ratio(0.88)in serum,RBD protein formulated with CpG 1826 adjuvant induced Th1-type predominant immune response in mice.Conclusions RBD subunit vaccine formulated with CpG 1826 adjuvant induced the strong cellular and humoral immune responses in mice,providing a scientific basis for the adjuvant application of SARS-CoV-2 subunit vaccines.
Severe acute respiratory syndrome coronavirus 2Receptor-binding domainSubunit vaccineCpG 1826Immunogenicity
万方数据
维普
